T-cell-depleting antibodies and risk of cancer after transplantation

Transplantation

Volumn 97, Issue 8, 2014, Pages 808-809

  Snanoudj, Renaud ^a   Legendre, Christophe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute rejection; Posttransplant malignancy; T cellYdepleting antibodies

Indexed keywords

AUTOANTIBODIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; T-LYMPHOCYTES; UROGENITAL NEOPLASMS;

EID: 84899485405     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442780.88287.e7     Document Type: Note

References (6)

1. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers inpeople with HIV/AIDS compared with immunosuppressed transplantrecipients: a meta-analysis. Lancet 2007; 370: 59.
2. Schnitzbauer AA, Schlitt HJ, Geissler EK. Influence of immunosuppressivedrugs on the recurrence of hepatocellular carcinoma after livertransplantation: a gap between basic science and clinical evidence.Transplantation 2011; 91: 1173.
3. Lim WH, Turner RM, Chapman JR, et al. Acute rejection, T-cell depletingantibodies and cancer after transplantation. Transplantation2014; 97: 817.
4. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantationin the United States. Am J Transplant 2004; 4: 905.
5. Opelz G, Döhler B. Lymphomas after solid organ transplantation: acollaborative transplant study report. Am J Transplant 2004; 4: 222.
6. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonistsfor kidney transplant recipients. Cochrane Database Syst Rev2010;CD003897.